STUDY SEARCH RESULTS

1 study found for your search request:  6482-015

Belzutifan/MK-6482 for the treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic N...
Condition: Pheochromocytoma/paraganglioma, Pancreatic neuroendocrine tumor, von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2a mutated cancers
Minimum Age: 12 years, Maximum Age: N/A
Gender: All
Study ID: NCT04924075
Status: Recruiting
Has Enrolling Locations in US or Canada




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site